Bibliography
- Rollison DE, Howlader N, Smith MT, Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001 – 2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52
- Vardiman JW, Thiele J, Arber DA, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51
- Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:284-93
- Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009;115:3842-7
- Mesa RA, Green A, Barosi G, MPN-associated myelofibrosis (MPN-MF). Leuk Res 2011;35:12-13
- Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38
- Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011;2011:208-14
- Le Bousse-Kerdiles MC, Martyre MC, Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw 2008;19:69-80
- Verstovsek S, Kantarjian H, Mesa RA, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
- Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009;4:33-40
- Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60:233-45
- Barbui T, Barosi G, Birgegard G, Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-70
- Morel P, Duhamel A, Hivert B, Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010;115:4350-5
- Mesa RA, Verstovsek S, Cervantes F, Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31(6):737-40
- Cervantes F, Dupriez B, Pereira A, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
- Gangat N, Caramazza D, Vaidya R, DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-7
- Passamonti F, Cervantes F, Vannucchi AM, A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-8
- Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nat Rev Drug Discov 2012;11:103-4
- Mesa RA, Niblack J, Wadleigh M, The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76
- Scherber RM, Dueck AC, Johansson P, Symptomatic burden in myelofibrosis (MF): prospective international assessment in 128 MF patients. J Clin Oncol 2011;29(Suppl): abstract 6610
- Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011;2011:222-30
- Tefferi A. How I treat myelofibrosis. Blood 2011;117:3494-504
- Alchalby H, Badbaran A, Zabelina T, Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010;116:3572-81
- Patriarca F, Bacigalupo A, Sperotto A, Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008;93:1514-22
- Ballen KK, Shrestha S, Sobocinski KA, Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358-67
- Stewart WA, Pearce R, Kirkland KE, The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010;45:1587-93
- Siragusa S, Passamonti F, Cervantes F, Tefferi A. Survival in young patients with intermediate-/ high-risk myelofibrosis: estimates derived from databases for non transplant patients. Am J Hematol 2009;84:140-3
- Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012;120:1367-79
- Rondelli D, Barosi G, Bacigalupo A, Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005;105:4115-19
- Kröger N, Alchalby H, Klyuchnikov E, JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009;113:1866-8
- Tefferi A, Mesa RA, Nagorney DM, Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000;95:2226-33
- Mesa RA, Nagorney DS, Schwager S, Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361-70
- Martinez-Trillos A, Gaya A, Maffioli M, Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233-7
- Siragusa S, Vaidya R, Tefferi A. Hydroxyurea effect on marked splenomegaly associated with primary myelofibrosis: response rates and correlation with JAK2V617F allele burden. Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/4971
- Harrison C, Kiladjian JJ, Al-Ali HK, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
- Barosi G, Grossi A, Comotti B, Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001;114:78-83
- Mesa RA, Steensma DP, Pardanani A, A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-41
- Mesa RA, Yao X, Cripe LD, Lenalidomide and prednisone for myelofibrosis: eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116:4436-8
- Tefferi A, Cortes J, Verstovsek S, Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-64
- Abgrall JF, Guibaud I, Bastie JN, Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006;91:1027-32
- Jabbour E, Thomas D, Kantarjian H, Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 2011;118:899-902
- Jakafi® prescribing information. Incyte Corp. Available from: http://www.incyte.com/products/uspi_jakafi.pdf
- Canada Newswire. (PR)JAKAVI® the first medication to receive Health Canada approval to treat patients with myelofibrosis. Available from: http://www.newswire.ca/en/story/1003655/-pr-jakavi-the-first-medication-to-receive-health-canada-approval-to-treat-patients-with-myelofibrosis
- Novartis. Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis. Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1636508.shtml
- Verstovsek S, Mesa RA, Gotlib J, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
- Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-29
- Panteli KE, Hatzimichael EC, Bouranta PK, Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130:709-15
- Tefferi A, Vaidya R, Caramazza D, Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-63
- Quintas-Cardama A, Vaddi K, Liu P, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17
- Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188-91
- Verstovsek S, Kantarjian HM, Estrov Z, Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120:1202-9
- Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365:1455-7
- Verstovsek S, Mesa RA, Gotlib J, Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I [abstract 800]. ASH Annual Meeting; 2012
- Cervantes F, Kiladjian JJ, Niederwieser D, Long-term safety, effiacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) [abstract 801]. ASH Annual Meeting; 2012
- Talpaz M, Hamburg SI, Jamieson K, Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50 – 100x109/L. J Clin Oncol 2012;30. Available from: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/6630?sid=000067e3-547c-48cd-a5aa-31124951bede
- YM BioSciences. Reports operational and financial results for the third quarter of fiscal 2012. Available from: http://www.ymbiosciences.com/investors/Press-Releases/Press-Release-Details/2012/YM-BioSciences-Reports-Operational-and-Financial-Results-for-the-Third-Quarter-of-Fiscal-20121129442/default.aspx
- Cell Therapeutics, Inc. Cell Therapeutics completes acquisition of pacritinib a highly selective JAK2 inhibitor; phase 3 study in patients with myelofibrosis and low platelet counts targeted to start in Q4-2012. Available from: http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&cat=news&id=1701881
- Santos FP, Kantarjian HM, Jain N, Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6
- Wernig G, Kharas MG, Okabe R, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20
- Geron I, Abrahamsson AE, Barroga CF, Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008;13:321-30
- Pardanani A, Gotlib JR, Jamieson C, Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-96
- Pardanani AD, Cortes JE, Cervantes F, JAKARTA: a phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly. J Clin Oncol 2012;30. Available from: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/TPS6639?sid=b31f33aa-d8e3-4ca7-bf1e-93a70dfb7858
- Pardanani A, Lasho T, Smith G, CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441-5
- Tyner JW, Bumm TG, Deininger J, CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232-40
- Pardanani AD, Caramazza D, George G, Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol 2011;29
- Pardanani A, Gotlib J, Gupta V, An expanded multicenter phase I/II study of CYT387, a JAK- 1/2 inhibitor for the treatment of myelofibrosis. ASH Annual Meeting Abstr 2011;118:3849. Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3849?maxtoshow=&hits=10&RESULTFORMAT=1&author1=Pardanani&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&volume=118&resourcetype=HWCIT
- Tefferi A, Barosi G, Mesa RA, International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-503
- Gale RP, Barosi G, Barbui T, What are RBC-tranfusion-dependence and -independence? Leuk Res 2011;35:8-11
- Hart S, Goh KC, Novotny-Diermayr V, SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011;25:1751-9
- Deeg HJ, Odenike O, Scott BL, Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. J Clin Oncol 2011;29(Suppl): abstract 6515
- Komrokji RS, Wadleigh M, Seymour JF, Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstr 2011;118:282
- Ma L, Zhao B, Walgren R, Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2 V617F-induced hematologic malignancy models. Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/4087
- Verstovsek S, Mesa RA, Rhoades SK, Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/2814
- Vannucchi AM, Bogani C, Bartalucci N, The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/2914
- Guglielmelli P, Barosi G, Rambaldi A, Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118:2069-76
- Tefferi A, Verstovsek S, Barosi G, Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-9
- Mesa RA, Pardanani AD, Hussein K, Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010;85:129-30
- Begna KH, Mesa RA, Pardanani A, A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25:301-4
- Begna KH, Pardanani A, Mesa R, Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012;87:66-8
- Mascarenhas J, Mercado A, Rodriguez A, Prolonged low dose therapy with a pan-deacetylase inhibtor, panobinostat (LBH589), in patients with myelofibrosis. Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/794
- DeAngelo DJ, Tefferi A, Fiskus W, A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essentialtThrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/630
- Rambaldi A, Dellacasa CM, Finazzi G, A pilot study of the hdistone-eacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-55
- Odenike O, Godwin JE, van Besien K, Phase II trial of decitabine in myelofibrosis with myeloid metaplasia J Clin Oncol. 2007;25(Suppl):7088
- Barker HE, Erler JT. The potential for LOXL2 as a target for future cancer treatment. Future Oncol 2011;7:707-10
- Kiladjian JJ, Cassinat B, Chevret S, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-72
- Kiladjian JJ, Cassinat B, Turlure P, High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006;108:2037-40
- Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117:4706-15
- Quintas-Cardama A, Kantarjian H, Manshouri T, Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-24
- Ianotto JC, Kiladjian JJ, Demory JL, PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 2009;146:223-5
- Gowin K, Thapaliya P, Samuelsson J, Experience with pegylated Interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012;97:1570-3